GGrantIndex
← Leaderboards

Anna R Hemnes

Vanderbilt University Medical Center

$10,524,693
Attributed
$14,211,239
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,955,117 · 10
FDA$1,600,000 · 1

By mechanism

R01$11,370,732 · 4
P01$8,343,878 · 1
U01$1,456,063 · 1
K08$627,480 · 1
K24$458,576 · 1
R03$175,000 · 1

Top collaborators

Most similar at Vanderbilt University Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Pulmonary Arterial Hypertension

Research focus

Pulmonary Arterial HypertensionResponseBlood VesselsDiagnosisPulmonary HypertensionLungPhenotypeMolecularMetabolicGeneticPrecision MedicineAffectPathway InteractionsCohortInsulin ResistanceFuturePulmonary Artery StructureHemodynamicsGrantBaseBiologyGenomicsAnimal ModelPharmaceutical Preparations

Grant awards (46)

Genomic and Circulating Predictors of PAH response$785,069
R01 · FY2025 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$699,718
R01 · FY2025 · HL
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2025 · FD
Mentorship in Pulmonary Vascular Disease$114,644
K24 · FY2025 · HL · contact PI
Genomic and Circulating Predictors of PAH response$785,069
R01 · FY2024 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$685,723
R01 · FY2024 · HL
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2024 · FD
Mentorship in Pulmonary Vascular Disease$114,644
K24 · FY2024 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$653,505
R01 · FY2023 · HL
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2023 · FD
FLI1 in Pulmonary Arterial Hypertension$175,000
R03 · FY2023 · TR · contact PI
Mentorship in Pulmonary Vascular Disease$114,644
K24 · FY2023 · HL · contact PI
2023 Grover Conference$10,000
R13 · FY2023 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$798,826
R01 · FY2022 · HL
Genomic and Circulating Predictors of PAH response$622,064
R01 · FY2022 · HL · contact PI
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals$400,000
R01 · FY2022 · FD
Mentorship in Pulmonary Vascular Disease$114,644
K24 · FY2022 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,678,313
P01 · FY2021 · HL · contact PI
Genomic and Circulating Predictors of PAH response$622,064
R01 · FY2021 · HL · contact PI
Genomic and Circulating Predictors of PAH response$171,248
R01 · FY2021 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,652,537
P01 · FY2020 · HL · contact PI
Genomic and Circulating Predictors of PAH response$622,064
R01 · FY2020 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,653,141
P01 · FY2019 · HL · contact PI
Genomic and Circulating Predictors of PAH response$622,064
R01 · FY2019 · HL · contact PI
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$378,456
R01 · FY2019 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,654,352
P01 · FY2018 · HL
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$431,210
R01 · FY2018 · HL · contact PI
A molecular phenotype of combined pulmonary hypertension$300,898
U01 · FY2018 · HL · contact PI
Hormonal, Metabolic and Signaling Interactions in PAH$1,705,535
P01 · FY2017 · HL
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$514,988
R01 · FY2017 · HL · contact PI
A molecular phenotype of combined pulmonary hypertension$304,885
U01 · FY2017 · HL · contact PI
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$158,000
R01 · FY2017 · HL · contact PI
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$591,282
R01 · FY2016 · HL · contact PI
A molecular phenotype of combined pulmonary hypertension$308,792
U01 · FY2016 · HL · contact PI
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$17,284
R01 · FY2016 · HL · contact PI
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension$612,098
R01 · FY2015 · HL · contact PI
A molecular phenotype of combined pulmonary hypertension$188,960
U01 · FY2015 · HL · contact PI
A molecular phenotype of combined pulmonary hypertension$117,026
U01 · FY2015 · HL · contact PI
A molecular phenotype of combined pulmonary hypertension$235,502
U01 · FY2014 · HL · contact PI
Gender differences and endothelin responses in right ventricular afterload stress$125,496
K08 · FY2012 · HL · contact PI
Gender differences and endothelin responses in right ventricular afterload stress$125,496
K08 · FY2011 · HL · contact PI
Gender differences and endothelin responses in right ventricular afterload stress$125,496
K08 · FY2010 · HL · contact PI
Gender differences and endothelin responses in right ventricular afterload stress$125,496
K08 · FY2009 · HL · contact PI
Gender differences and endothelin responses in right ventricular afterload stress$125,496
K08 · FY2008 · HL · contact PI
PDE5 Inhibition Modulates Right Ventricular Failure$58,036
F32 · FY2006 · HL · contact PI
PDE5 Inhibition Modulates Right Ventricular Failure$55,352
F32 · FY2005 · HL